<DOC>
	<DOC>NCT01008774</DOC>
	<brief_summary>Primary objective: - Rate of complete chemotherapy induced alopecia (WHO grade III or IV, physician grading) Secondary objective: - Compliance to scalp cooling procedure - Received number of cycles of chemotherapy in each subgroup - Patient perception of scalp cooling procedure - Side effects of scalp cooling systems</brief_summary>
	<brief_title>START: Swiss Taxotere Alopecia Prevention Trial</brief_title>
	<detailed_description />
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Alopecia Areata</mesh_term>
	<criteria>Any solid tumor malignancy receiving docetaxel (TaxotereÂ®) 1st line chemotherapy treatment with the exception of regimen containing concomitant anthracycline treatment; sequential anthracycline/docetaxel treatment is permitted. Performance Status ECOG &lt;= 2 Absence of alopecia at inclusion Chemotherapy regimen including concomitant anthracycline treatment Raynaud's disease or phenomenon Cold agglutinin disease Cryoglobulinemia Cryofibrinogenemia Scalp metastasis Pregnancy or Lactation Preexisting alopecia of any grade; notably androgenetic alopecia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>